laboratori corpor america hold
diagnost tool
posit lh decis divest covanc
food segment focu busi run capit
lh announc morn deal divest covanc food solut busi
eurofin scientif cash revenu multipl segment
revenu note higher revenu multipl lh
paid acquir covanc trail revenu confirm
lh morn growth rate busi in-lin core diagnost
busi manag recent guid covanc
food busi ran oper margin believ move free cash
lh focu core lab cro busi view attract
lh expect deal close slightli dilut ep howev
deal contempl adj ep guid posit
deal rational multipl lh fetch sale expect lh acceler
 buyback pay debt perhap order lh remain top pick us
reiter buy rate pt
deal lh enter definit agreement sell covanc food solut
segment eurofin scientif eufi pa global group laboratori activ food
environ pharma product test cash multipl
note larger multipl lh paid acquir covanc deal
expect close
number lh indic covanc food solut growth in-lin
overal busi estim oper margin profil
similar diagnost segment whole oper margin lh indic
us food solut segment appear abl scale pace
core busi lh expect deal slightli dilut ep though
alreadi incorpor deal current adj ep guid
lh remind us segment report core diagnost busi thu upon
close plan lower lh lab revenu approxim
updat model time lh expect updat revenu guid deal
proce expect proce expect lh acceler
pace core specul slant core lab dx segment
ie find deal similar mount sinai health system perhap increas
foothold diagnost servic relat precis medicin cro follow
share buyback follow debt paydown perhap order lh leverag ratio
today gross debt ttm adj ebitda target rang time
busi lh acquir covanc food solut part larger deal
covanc oper busi segment year covanc food solut
global provid innov product design product integr servic end-
user segment span global food suppli chain integr network
facil across us uk singapor
price close busi april
labcorp lead refer laboratori test compani
also oper covanc drug develop
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
recent oper result look back result
last week lh deliv strong beat guid rev our/street
expect driven improv organ growth fx ad bp revenue
growth expect add year view lh winner tax
reform pama implement expect lh well posit
execut reiter lh one top pick came away
call increment posit growth prospect covanc
diagnost segment reiter buy pt adj
ep
covanc women health drove beat adj ep
beat rev y/i beat us street
covanc y/i drove beat top labcorp
diagnost rev beat street miss
rev/req miss pama cut volum beat
 volum beat organ volum grew vs
step organ volum surg
lh see growth varieti test women health organ rev grew
y/i drove point revenue growth
contract lh chairman ceo dave king indic lh involv
extens consist howev updat report
obviou flag risk howev contact open lh well
think likelihood contact aet could open
includ lh net-net could net winner given larger health plan
aet view
covanc covanc rev y/i top
street fx ad y/i growth covanc backlog
lh expect convert
revenue net order increas q/q
net book-to-bil end lh
track deliv cost synergi year integr chiltern
guid call lh rais revenue guid y/i
despit ep beat lh maintain adj ep guid
guid bake headwind adopt
guid assum growth lh diagnost
growth covanc led chiltern acquisit
anniversari mid- high-single-digit organ growth covanc
model got overhaul call restat rais full year
actual revenu reflect adopt restat result
reduct labcorp diagnost revenu
reduct increas drug develop revenu
increas result total net increas
revenu call rais rev
y/i beat fx rais adj ep
y/i mainli carri forward beat call also
rais rev adj ep y/i
make chang model today
 lh invest deal expect pace newli
announc deal could continu similar rate wouldnt surpris
see lh execut larger number dx deal expect lh priorit
 integr come showcas growth
expect outweigh buyback lh repurchas stock
author lh invest
acquisit lh end billion debt hover
gross leverag ratio ebitda recal lh guidanc contempl free cash
flow billion unchang thu expect see acquisit not-too-
distant futur certainli
diagnost tool
laboratori corpor america hold
pama chanc tweak labcorp ceo dave king respons question
affirm view acla vs hh case acla compel
power case acla ask go back congress said would
provid market-bas price inclus larger pool lab king hold
optim rate could adjust year
believ stock price outcom like believ may
see relief form less draconian rate set year
think may visibl within next month
mr king response/stat call regard case
ive said along first time sue govern uphil
battl nevertheless merit convinc power case
congress wrote statut specif instruct secretari
someth someth market survey includ hospit
secretari wrote rule exclud hospit unit state
secretari didnt congress said legal believ mean rule
set asid seek relief seek chang
payment cut seek rule set asid secretari told
go back congress said
right case judg rule favor rule set asid
secretari restart process rulemak end rule carri
congression intent would impact reset
reduct come market assess lab industri
exactli congress ask secretari congress said secretari
get medicar market didnt say get medicar absolut lowest price everi
singl test seem secretari tri achiev
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
laboratori corpor america hold
diagnost tool
laboratori corpor america hold
